阿托伐他汀钙联合尼可地尔对经皮冠状动脉介入治疗患者的心脏保护作用研究

A Study on Protective Effect of Atorvastatin Calcium Combined with Nicorandil on Myocardium of the Patients Undergoing Percutaneous Coronary Artery Intervention

目的:探讨阿托伐他汀钙联合尼可地尔对经皮冠状动脉介入治疗患者的心脏保护作用。方法:选取2009年1月-2012年12月本院收治的104例经皮冠状动脉介入治疗的不稳定型心绞痛患者为研究对象,随机分为两组,每组52例。治疗组术前给予尼可地尔、阿托伐他汀钙。对照组单纯给予阿托伐他汀钙。测定并记录两组患者术后24h肌钙蛋白I、肌酸肌酶同工酶、高敏C反应蛋白的水平。结果:联合治疗组术后肌钙蛋白I阳性例数、肌酸肌酶同工酶大于参考值上限2倍的例数、高敏C反应蛋白水平较阿托伐他汀组显著减少,差异具有统计学意义(P<0.05)。结论:阿托伐他汀钙联合尼可地尔能够使经皮冠状动脉介入治疗患者术后心肌损伤减少、高敏C反应蛋白水平显著下降,可以更好地保护心肌、抑制炎症反应,有利于减少经皮冠状动脉介入治疗术后心脏事件的发生。

Objective： To investigate the protective effect of atorvastatin calcium combined with nicorandil of the patients undergoing percutaneous coronary artery intervention. Method： 104 patients with unstable angina in our hospital from Jan 2009 to Dec 2012 were randomly divided into two groups, 52 cases for esch one.Torvastatin calcium combined with nicorandil were administrated to the combined treatment group and atorvastatin calcium was administrated to the control group alone before operation. The levels of Troponin I, CK-MB and hs-CRP of the patients in the two groups at 24 h after operation were measured and recorded. Result： The number of cases with positive Troponin I, the number of cases whose level of CK-MB were 2 times higher than the maximum reference value and the level of hs-CRP of the combined treatment group were lower obviously than those of the control group after operation. The differences had statistical significance （ P〈0.05 ） . Conclusion： Atorvastatin calcium combined with nicorandil can ease postoperative myocardial damage of patients with percntaneous coronary artery intervention, and obviously reduce the level of hs-CRP. It can provide better myocardial preservation and inhibit the flammatory reaction, therefore, it helps to reduce the incidence of cardiac events after percutaneous coronary artery intervention.